As of May 27
| -0.61 / -1.09%|
The 34 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 63.79, with a high estimate of 76.17 and a low estimate of 45.32. The median estimate represents a +15.05% increase from the last price of 55.44.
The current consensus among 35 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.